Zymeworks Price to Book Ratio 2016-2022 | ZYME

Historical price to book ratio values for Zymeworks (ZYME) over the last 10 years. The current price to book ratio for Zymeworks as of January 25, 2023 is 2.54.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Zymeworks Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2023-01-26 9.75 2.53
2022-06-30 5.30 $3.85 1.38
2022-03-31 6.55 $4.89 1.34
2021-12-31 16.39 $5.34 3.07
2021-09-30 29.04 $5.99 4.85
2021-06-30 34.69 $6.95 4.99
2021-03-31 31.58 $8.17 3.87
2020-12-31 47.26 $8.90 5.31
2020-09-30 46.58 $9.44 4.93
2020-06-30 36.07 $10.78 3.35
2020-03-31 35.47 $11.47 3.09
2019-12-31 45.46 $6.21 7.32
2019-09-30 24.80 $7.87 3.15
2019-06-30 22.00 $8.53 2.58
2019-03-31 16.18 $5.30 3.05
2018-12-31 14.68 $5.64 2.60
2018-09-30 15.70 $5.31 2.96
2018-06-30 14.78 $5.84 2.53
2018-03-31 12.02 $3.71 3.24
2017-12-31 7.59 $4.58 1.66
2017-06-30 8.35 $3.83 2.18
2017-09-30 7.98 $3.26 2.45
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.616B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.571B 9.49
GSK (GSK) United Kingdom $71.996B 8.97
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.414B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.676B 25.16
Biohaven (BHVN) United States $1.305B 0.00
Emergent Biosolutions (EBS) United States $0.671B 5.28
ADC Therapeutics SA (ADCT) Switzerland $0.359B 0.00
Ambrx Biopharma (AMAM) United States $0.083B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00